No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
(r)-(1-(4-fluorophenyl)-6-((1-methyl-1h-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1h-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone |
Pyrazole |
- |
- |
- |
[1] 75 |
2 |
17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one |
- |
- |
- |
- |
[1] 75 |
3 |
17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one |
- |
- |
- |
- |
[1] 75 |
4 |
18f-dopa |
- |
- |
- |
- |
[2] 6, 75 |
5 |
1h-pyrazol |
Pyrazole |
- |
- |
- |
[2] 46, 75 |
6 |
Abiraterone |
Abiraterone |
D09701 |
- |
- |
[2] 75, 81 |
7 |
Abiraterone acetate |
Abiraterone |
D09701 |
- |
- |
[2] 75, 81 |
8 |
Acetate |
Acetate |
- |
- |
- |
[40] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
9 |
Acthrel |
Corticorelin ovine triflutate |
D03592 |
[2] CRHR1, CRHR2 |
[3] Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction |
[1] 75 |
10 |
Aspartate |
Aspartic acid |
D00013 |
- |
- |
[3] 13, 75, 299 |
11 |
Atr-101 |
- |
- |
- |
- |
[2] 75, 81 |
12 |
Azd4017 |
Azd4017 |
- |
- |
- |
[1] 75 |
13 |
Azd4017 and prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 75 |
14 |
Bexarotene |
Bexarotene |
D03106 |
[3] RXRA, RXRB, RXRG |
[15] Adipocytokine signaling pathway, Bile secretion, Gastric cancer, Hepatitis C, Non-alcoholic fatty liver disease (NAFLD), Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer |
[2] 13, 75 |
15 |
Cabergoline |
Cabergoline |
D00987 |
[2] DRD2, PRL |
[12] Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
[3] 6, 74, 75 |
16 |
Calcium |
Calcium |
- |
- |
- |
[24] 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
17 |
Calcium carbonate |
Calcium carbonate |
D00932, D10802 |
- |
- |
[7] 13, 19, 46, 75, 96, 235, 299 |
18 |
Carbonate |
Carbonate ion |
- |
- |
- |
[10] 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
19 |
Cor-003 |
- |
- |
- |
- |
[1] 75 |
20 |
Cort125134 |
Relacorilant |
D11336 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 75 |
21 |
Corticotropin |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[7] 2, 13, 46, 75, 78, 84, 222 |
22 |
Corticotropin-releasing hormone |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 75 |
23 |
Cushing's syndrome confirmation |
- |
- |
- |
- |
[1] 75 |
24 |
Cyclo((diaminoethyl-carbamate)hypro-phg-(d)trp-lys-tyr(bzl)-phe) di-aspartate |
Aspartic acid |
D00013 |
- |
- |
[1] 75 |
25 |
Ddavp |
Desmopressin |
D00291, D02235 |
[2] AVPR2, F8 |
[4] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
[2] 75, 288 |
26 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[20] 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
27 |
Dostinex |
Cabergoline |
D00987 |
[2] DRD2, PRL |
[12] Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
[1] 75 |
28 |
Dotatate |
Dotatate |
- |
- |
- |
[3] 41, 75, 84 |
29 |
Dotatate pet-ct |
Dotatate |
- |
- |
- |
[1] 75 |
30 |
Eplerenone |
Eplerenone |
D01115 |
[1] NR3C2 |
[1] Aldosterone-regulated sodium reabsorption |
[3] 75, 113, 215 |
31 |
F-dopa pet ct |
- |
- |
- |
- |
[1] 75 |
32 |
Gefitinib |
Gefitinib |
D01977 |
[1] EGFR |
[45] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
[1] 75 |
33 |
Genotropin 12mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
34 |
Genotropin 5.3mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
35 |
Genotropin miniqu |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
36 |
Genotropin miniquick 0.2mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
37 |
Genotropin miniquick 0.4mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
38 |
Genotropin miniquick 0.6mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
39 |
Genotropin miniquick 0.8mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
40 |
Genotropin miniquick 1.0mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
41 |
Genotropin miniquick 1.2mg |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[3] 74, 75, 78 |
42 |
Glucophage (metformin) |
Metformin |
D00944, D04966 |
[2] PRKAA1, PRKAA2 |
[19] AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
[2] 46, 75 |
43 |
Hra052015 |
- |
- |
- |
- |
[1] 75 |
44 |
Hra052015 (mifepristone) |
Mifepristone |
D00585 |
[2] NR3C1, PGR |
[5] Breast cancer, Estrogen signaling pathway, Neuroactive ligand-receptor interaction, Oocyte meiosis, Progesterone-mediated oocyte maturation |
[1] 75 |
45 |
Hydrocortisone |
Hydrocortisone |
D00088 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[8] 6, 53, 75, 78, 81, 83, 97, 299 |
46 |
Insulin |
- |
- |
- |
- |
[5] 13, 46, 75, 78, 299 |
47 |
Ketoconazole |
Ketoconazole |
D00351 |
[1] CYP17A1 |
[6] Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis |
[3] 8, 13, 75 |
48 |
L0006cp03a |
- |
- |
- |
- |
[1] 75 |
49 |
Lapatinib |
Lapatinib |
D04024, D08108 |
[2] EGFR, ERBB2 |
[47] Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Platinum drug resistance, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Tight junction |
[3] 34, 74, 75 |
50 |
Lci699 |
- |
- |
- |
- |
[1] 75 |
51 |
Levoketoconazole |
Levoketoconazole |
D10950 |
- |
- |
[1] 75 |
52 |
Levoketozonazole |
- |
- |
- |
- |
[1] 75 |
53 |
Liraglutide |
Liraglutide |
D06404 |
[1] GLP1R |
[3] Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[3] 6, 75, 193 |
54 |
Matyrapone |
- |
- |
- |
- |
[1] 75 |
55 |
Metformin |
Metformin |
D00944, D04966 |
[2] PRKAA1, PRKAA2 |
[19] AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
[16] 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
56 |
Methionine |
Methionine |
D00019, D04983 |
- |
- |
[6] 34, 75, 84, 93, 229, 300 |
57 |
Metopirone 250 mg capsules/cormeto |
Metyrapone |
D00410, D05019 |
[1] CYP11B1 |
[4] Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Steroid hormone biosynthesis |
[1] 75 |
58 |
Metyrapone |
Metyrapone |
D00410, D05019 |
[1] CYP11B1 |
[4] Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Steroid hormone biosynthesis |
[2] 75, 193 |
59 |
Mifedren |
- |
- |
- |
- |
[1] 75 |
60 |
Mifepristone |
Mifepristone |
D00585 |
[2] NR3C1, PGR |
[5] Breast cancer, Estrogen signaling pathway, Neuroactive ligand-receptor interaction, Oocyte meiosis, Progesterone-mediated oocyte maturation |
[1] 75 |
61 |
Nizoral |
Ketoconazole |
D00351 |
[1] CYP17A1 |
[6] Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis |
[1] 75 |
62 |
Octreotide |
Octreotide |
D00442, D06495 |
[1] SSTR2 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[7] 67, 75, 84, 85, 89, 193, 227 |
63 |
Orocal |
- |
- |
- |
- |
[1] 75 |
64 |
Osilodrostat |
Osilodrostat |
D11061 |
[1] CYP11B2 |
[3] Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis |
[1] 75 |
65 |
Osilodrostat 10mg |
Osilodrostat |
D11061 |
[1] CYP11B2 |
[3] Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis |
[1] 75 |
66 |
Osilodrostat 1mg |
Osilodrostat |
D11061 |
[1] CYP11B2 |
[3] Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis |
[1] 75 |
67 |
Osilodrostat 20mg |
Osilodrostat |
D11061 |
[1] CYP11B2 |
[3] Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis |
[1] 75 |
68 |
Osilodrostat 5mg |
Osilodrostat |
D11061 |
[1] CYP11B2 |
[3] Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis |
[1] 75 |
69 |
Ossein hydroxyapatite |
- |
- |
- |
- |
[1] 75 |
70 |
Osteopor |
- |
- |
- |
- |
[1] 75 |
71 |
Ovine corticotropin-releasing hormone (ocrh) |
Corticotropin |
D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 75 |
72 |
Pasireotide |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[3] 67, 74, 75 |
73 |
Pasireotide 0.6 mg/ml |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 75 |
74 |
Pasireotide diaspartate |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 75 |
75 |
Pasireotide lar |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[2] 67, 75 |
76 |
Pasireotide pamoate |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 75 |
77 |
Pasireotide s.c. |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 75 |
78 |
Pasireotide with or without cabergoline |
Cabergoline, Pasireotide |
D00987, D10147 |
[6] DRD2, PRL, SSTR1, SSTR2, SSTR3, SSTR5 |
[14] Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
[1] 75 |
79 |
Pentetreotide |
Pentetreotide |
D01859 |
- |
- |
[1] 75 |
80 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[38] 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
81 |
R-roscovitine |
Seliciclib |
- |
- |
- |
[1] 75 |
82 |
Relacorilant |
Relacorilant |
D11336 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 75 |
83 |
Rosiglitazone |
Rosiglitazone |
D00596, D08491 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[5] 46, 75, 97, 222, 265 |
84 |
Rosiglitazone maleate |
Rosiglitazone |
D00596, D08491 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[3] 46, 75, 265 |
85 |
Rvg 08938 |
- |
- |
- |
- |
[1] 75 |
86 |
Rvg 15375 |
- |
- |
- |
- |
[1] 75 |
87 |
Rvg 18236 |
- |
- |
- |
- |
[2] 75, 227 |
88 |
Seliciclib |
Seliciclib |
- |
- |
- |
[2] 75, 299 |
89 |
Signifor |
Pasireotide |
D10147 |
[4] SSTR1, SSTR2, SSTR3, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 75 |
90 |
Sitagliptin |
Sitagliptin |
D08516 |
[1] DPP4 |
[1] Protein digestion and absorption |
[3] 75, 233, 299 |
91 |
Som230 |
- |
- |
- |
- |
[2] 74, 75 |
92 |
Som230 300µg |
- |
- |
- |
- |
[1] 75 |
93 |
Som230 600µg |
- |
- |
- |
- |
[1] 75 |
94 |
Som230 900µg |
- |
- |
- |
- |
[1] 75 |
95 |
Som230 lar 10 mg |
- |
- |
- |
- |
[1] 75 |
96 |
Som230 lar 30 mg |
- |
- |
- |
- |
[1] 75 |
97 |
Som230 lar, 20 mg |
- |
- |
- |
- |
[1] 75 |
98 |
Som230 s.c. |
- |
- |
- |
- |
[1] 75 |
99 |
Som230, 300micrograms |
- |
- |
- |
- |
[1] 75 |
100 |
Som230, 600 micrograms |
- |
- |
- |
- |
[1] 75 |
101 |
Som230, 900 micrograms |
- |
- |
- |
- |
[1] 75 |
102 |
Som230b |
- |
- |
- |
- |
[1] 75 |
103 |
Somatropin |
Somatotropin |
D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[15] 2, 3, 19, 46, 74, 75, 78, 96, 113, 193, 195, 265, 274, 276, 299 |
104 |
Tadalafil |
Tadalafil |
D02008 |
[1] PDE5A |
[3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
[6] 6, 51, 75, 84, 86, 113 |
105 |
Tretinoin |
Tretinoin |
D00094 |
[3] PML, RARA, RARB |
[12] Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis |
[2] 2, 75 |
106 |
Valsartan |
Valsartan |
D00400 |
[1] AGTR1 |
[14] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
[6] 57, 58, 66, 75, 218, 222 |